Spark Therapeutics Inc. (NASDAQ:ONCE) insider Barge Joseph La sold 3,000 shares of the stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $60.14, for a total value of $180,420.00. Following the sale, the insider now owns 8,325 shares of the company’s stock, valued at approximately $500,665.50. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Spark Therapeutics Inc. (NASDAQ:ONCE) opened at 62.97 on Thursday. Spark Therapeutics Inc. has a 52-week low of $21.20 and a 52-week high of $65.99. The firm’s 50-day moving average is $59.29 and its 200 day moving average is $49.45. The firm’s market capitalization is $1.93 billion.
Spark Therapeutics (NASDAQ:ONCE) last released its earnings results on Wednesday, August 10th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by $0.07. Spark Therapeutics had a negative return on equity of 26.96% and a negative net margin of 366.76%. The business had revenue of $1.29 million for the quarter, compared to analyst estimates of $1.17 million. During the same period in the prior year, the firm posted ($0.60) EPS. Spark Therapeutics’s revenue was up .0% on a year-over-year basis. Equities analysts anticipate that Spark Therapeutics Inc. will post ($3.96) EPS for the current year.
A number of analysts have recently issued reports on the company. Royal Bank Of Canada assumed coverage on Spark Therapeutics in a report on Tuesday, July 12th. They issued an “outperform” rating and a $70.00 target price for the company. Zacks Investment Research upgraded Spark Therapeutics from a “hold” rating to a “buy” rating and set a $66.00 target price for the company in a report on Thursday, August 11th. Cantor Fitzgerald restated a “buy” rating and issued a $94.00 target price on shares of Spark Therapeutics in a report on Thursday, August 11th. Jefferies Group restated a “hold” rating on shares of Spark Therapeutics in a report on Sunday, June 12th. Finally, Wedbush restated an “underperform” rating and issued a $29.00 target price on shares of Spark Therapeutics in a report on Monday, June 13th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $59.50.
Institutional investors have recently made changes to their positions in the company. Teacher Retirement System of Texas boosted its position in shares of Spark Therapeutics by 14.0% in the second quarter. Teacher Retirement System of Texas now owns 2,432 shares of the company’s stock worth $124,000 after buying an additional 299 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Spark Therapeutics during the second quarter worth $124,000. Legal & General Group Plc boosted its position in shares of Spark Therapeutics by 105.6% in the second quarter. Legal & General Group Plc now owns 2,714 shares of the company’s stock worth $138,000 after buying an additional 1,394 shares in the last quarter. AMG National Trust Bank purchased a new position in shares of Spark Therapeutics during the second quarter worth $256,000. Finally, State Board of Administration of Florida Retirement System purchased a new position in shares of Spark Therapeutics during the second quarter worth $307,000. 78.79% of the stock is currently owned by institutional investors.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.